Risk estimations and treatment decisions in early stage breast cancer: Agreement among oncologists and the impact of the 70-gene signature
Open Access
- 17 February 2014
- journal article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 50 (6), 1045-1054
- https://doi.org/10.1016/j.ejca.2014.01.016
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus StatementAnnals of Oncology, 2013
- Additional value and potential use of the 70-gene prognosis signature in node-negative breast cancer in daily clinical practiceAnnals of Oncology, 2009
- Clinical Application of the 70-Gene Profile: The MINDACT TrialJournal of Clinical Oncology, 2008
- Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER)The Lancet Oncology, 2007
- Population-Based Validation of the Prognostic Model ADJUVANT! for Early Breast CancerJournal of Clinical Oncology, 2005
- Microarray technology and its effect on breast cancer (re)classification and prediction of outcomeBreast Cancer Research, 2003
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerThe New England Journal of Medicine, 2002
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast CancerJournal of Clinical Oncology, 2001
- Prognostic factors in breast cancer: the predictive value of the Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single institutionEuropean Journal of Cancer, 2001